Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 388 participants.

Also called NCT02054897

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 388 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02054897
  • EudraCT 2013-000632-94
Other papers using this trial's data
  • Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial The lancet. Diabetes & endocrinology, 2017-04 DOI, PubMed 28110911
  • Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1-5 trials Diabetes, obesity & metabolism, 2018-09 DOI, PubMed 29687620, PMC6099273 In the PMC Open Access subset under CC BY-NC.
  • Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials Diabetes, obesity & metabolism, 2018-09 DOI, PubMed 29766634, PMC6099440 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Italy, Japan, Mexico, Romania, Russia, South Africa, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02054897. Randomized; double masking; primary purpose treatment. Start 2014-02-03 (actual); primary completion 2015-05-08 (actual). Results posted on 2018-01-23.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes
Acronym
SUSTAIN™1
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
semaglutide
Intervention (Drug)
placebo
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct02054897
Content hash
1730a07161f78a6d636423dd058a0df36e9d51613cfdfd9ca4c67548a131ddd6